Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.030 -0.060 (-2.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases 
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings For Editas Medicine ↗
 
Via Benzinga
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 2/28
Via Investor Brand Network
News headline image
Earnings Outlook For Editas Medicine ↗
 
Via Benzinga
News headline image
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. ↗
The company now has a chance to get its lead program out the door a bit sooner. 
Via The Motley Fool
News headline image
1 Beaten-Down Stock With 55% Upside, According to Wall Street ↗
The biotech has bounced back some in the past year. 
Via The Motley Fool
News headline image
Why Editas Medicine Stock Soared as Much as 42% Higher This Week ↗
The clinical-stage genome editing company dropped a couple of important announcements for shareholders. 
Via The Motley Fool
News headline image
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares? ↗
The company reported in-line sales for the fourth quarter, but shares soared by double digits. 
Via Investor's Business Daily
News headline image
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
The Latest Analyst Ratings for Editas Medicine ↗
 
Via Benzinga
News headline image
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. 
Via Benzinga
News headline image
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
2 Under-the-Radar Stocks With Incredible Upside Potential ↗
It's also important to consider their downsides. 
Via The Motley Fool
News headline image
Could Editas Medicine Become the Next CRISPR Therapeutics? ↗
The similarities between the pair are striking, but it might not be enough. 
Via The Motley Fool
News headline image
7 Mighty Healthcare Stocks Changing the Game of Medicine ↗
Thanks to the permanent relevance of medical innovations, investors ought to consider looking at these healthcare stocks. 
Via InvestorPlace
News headline image
Down 88%, Could Editas Medicine Be a Good Investment Now? ↗
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles. 
Via The Motley Fool
News headline image
3 Stocks to Buy in the Booming Field of Gene Editing ↗
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains. 
Via InvestorPlace
News headline image
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics ↗
These two are at very different stages of the clinical trials process. 
Via The Motley Fool
News headline image
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
News headline image
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals ↗
Editas isn't out of the woods yet, but it's better off than before. 
Via The Motley Fool
News headline image
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Bull Of The Day: Crispr Therapeutics ↗
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old... 
Via Talk Markets
News headline image
1 Promising Stock Down 66% That Could Skyrocket in 2024 ↗
Financial results aren't what matters most right now for this company. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.